J&J guns for quick drug OK in lung can­cer niche, tak­ing the first step chal­leng­ing As­traZeneca in EGFR

5 years ago
FDA+

Lil­ly part­ners with Unit­ed­Health to con­duct 're­al-world' study for its Covid-19 an­ti­body bam­lanivimab

5 years ago
Coronavirus

Four biotechs hit Wall Street with up­sized IPOs, each rais­ing more than $20M over their goals

5 years ago
Financing

Sutro's con­tin­ued PhI da­ta read­outs in­di­cate im­prov­ing re­sponse in ovar­i­an can­cer. What's next?

5 years ago
R&D

Covid-19 roundup: Mod­er­na of­fers glimpse at dura­bil­i­ty da­ta; Bribery scan­dals mar Sino­vac's rep­u­ta­tion

5 years ago
Coronavirus

BioCryst wins ap­proval for HAE pill and charges half-a-mil­lion dol­lars, but will any­one take it?

5 years ago
Pharma
FDA+

KBI plans $150M fa­cil­i­ty in Re­search Tri­an­gle Park with mys­tery co-in­vestor

5 years ago
Outsourcing

Penn re­searchers find a way through the labyrinth keep­ing CAR-T from sol­id tu­mors

5 years ago
Discovery
Cell/Gene Tx

News brief­ing: New senes­cent cell play launch­es with $12M; Jun­shi leads Se­ries C+ in­fu­sion for Chi­nese syn­thet­ic ...

5 years ago
News Briefing

A high-pro­file ‘an­gel’ joins the Sil­i­con Val­ley crew back­ing an an­ti-ag­ing up­start with an eye on PhII

5 years ago
Financing
R&D

Lau­ra Shawver is about to join a line­up of biotech CEOs en­joy­ing overnight for­tunes, cour­tesy of the biotech IPO boom

5 years ago
People
Financing

As UK awaits first Covid-19 vac­cine dos­es, Fau­ci and oth­ers crit­i­cize its 'hasty' de­ci­sion

5 years ago
Coronavirus

This is how Bern­stein divvies up a $40B Covid-19 vac­cine mar­ket among the lead­ers in the race to an ap­proval

5 years ago
Coronavirus

Mer­ck KGaA bets big on DNA dam­age up­start, push­ing $30M up­front and hefty in­cen­tives for a Lyn­parza pi­o­neer

5 years ago
Deals

Jaz­z's $1B SCLC drug fails com­bo tri­al, quash­ing hopes of quick full ap­proval. But how much does it mat­ter?

5 years ago
R&D

Covid-19 roundup: In­ovio en­lists plas­mid man­u­fac­tur­er to re­place the one it's in le­gal feud with; Cy­ber­at­tacks ...

5 years ago
Coronavirus

Mer­ck sells off its Mod­er­na stake af­ter mak­ing record gains amid the pan­dem­ic

5 years ago
Pharma

News brief­ing: Ex­elix­is pays $20M to in-li­cense a pre­clin­i­cal ADC for the pipeline; An­oth­er pre­clin­i­cal biotech ...

5 years ago
News Briefing

Ab­b­Vie eyes can­cer, im­munol­o­gy in lat­est pro­tein degra­da­tion pact, hand­ing Fron­tier Med­i­cines $55M up­front

5 years ago
Deals

J&J buys an ear­ly-stage gene ther­a­py for the eye — the on­ly known pro­gram for an un­der-the-radar biotech

5 years ago
Deals

Roche turns up the heat on Lil­ly with an­oth­er Gavre­to ap­proval, el­bow­ing its way in­to the thy­roid can­cer space

5 years ago
Pharma
FDA+

Long af­ter Mer­ck and Bris­tol My­ers cre­at­ed a multi­bil­lion-dol­lar mar­ket, the PD-1 lead­ers are once again duk­ing it ...

5 years ago
R&D
Pharma

Bay­er con­tin­ues its cell and gene ther­a­py push, en­velop­ing dif­fer­ent projects un­der one strate­gic roof while hunt­ing ...

5 years ago
Pharma
Cell/Gene Tx

A Genen­tech-part­nered Vi­jay Pande fa­vorite nabs $52M to ad­vance an AI pipeline

5 years ago
Financing
AI
First page Previous page 771772773774775776777 Next page Last page
A service from the Financial Times